精品国产精品免费在线观看|亚洲一级高清在线观看|亚洲乱码尤物193yw|亚洲综合狠狠99婷婷

      Cancer Biology & Therapy
      • 數(shù)據(jù)庫收錄SCIE
      • 創(chuàng)刊年份2002年
      • 年發(fā)文量81
      • H-index101

      Cancer Biology & Therapy

      期刊中文名:癌癥生物學(xué)與治療ISSN:1538-4047E-ISSN:1555-8576

      該雜志國際簡稱:CANCER BIOL THER,是由出版商Landes Bioscience出版的一本致力于發(fā)布醫(yī)學(xué)研究新成果的的專業(yè)學(xué)術(shù)期刊。該雜志以O(shè)NCOLOGY研究為重點,主要發(fā)表刊登有創(chuàng)見的學(xué)術(shù)論文文章、行業(yè)最新科研成果,扼要報道階段性研究成果和重要研究工作的最新進(jìn)展,選載對學(xué)科發(fā)展起指導(dǎo)作用的綜述與專論,促進(jìn)學(xué)術(shù)發(fā)展,為廣大讀者服務(wù)。該刊是一本國際優(yōu)秀雜志,在國際上有很高的學(xué)術(shù)影響力。

      基本信息:
      期刊簡稱:CANCER BIOL THER
      是否OA:未開放
      是否預(yù)警:
      Gold OA文章占比:79.27%
      出版信息:
      出版地區(qū):UNITED STATES
      出版周期:Monthly
      出版語言:English
      出版商:Landes Bioscience
      評價信息:
      中科院分區(qū):4區(qū)
      JCR分區(qū):Q2
      影響因子:4.4
      CiteScore:7
      雜志介紹 中科院JCR分區(qū) JCR分區(qū) CiteScore 投稿經(jīng)驗

      雜志介紹

      Cancer Biology & Therapy雜志介紹

      《Cancer Biology & Therapy》是一本以English為主的未開放獲取國際優(yōu)秀期刊,中文名稱癌癥生物學(xué)與治療,本刊主要出版、報道醫(yī)學(xué)-ONCOLOGY領(lǐng)域的研究動態(tài)以及在該領(lǐng)域取得的各方面的經(jīng)驗和科研成果,介紹該領(lǐng)域有關(guān)本專業(yè)的最新進(jìn)展,探討行業(yè)發(fā)展的思路和方法,以促進(jìn)學(xué)術(shù)信息交流,提高行業(yè)發(fā)展。該刊已被國際權(quán)威數(shù)據(jù)庫SCIE收錄,為該領(lǐng)域相關(guān)學(xué)科的發(fā)展起到了良好的推動作用,也得到了本專業(yè)人員的廣泛認(rèn)可。該刊最新影響因子為4.4,最新CiteScore 指數(shù)為7。

      本刊近期中國學(xué)者發(fā)表的論文主要有:

      • The role of lncRNA MSC-AS1/miR-29b-3p axis-mediated CDK14 modulation in pancreatic cancer proliferation and Gemcitabine-induced apoptosis.

        Author: Sun Y1, Wang P2, Yang W1, Shan Y1, Zhang Q1, Wu H3.

      • EGR1-induced upregulation of lncRNA FOXD2-AS1 promotes the progression of hepatocellular carcinoma via epigenetically silencing DKK1 and activating Wnt/β-catenin signaling pathway.

        Author: Lei T1, Zhu X2, Zhu K2, Jia F1, Li S1.

      • Expression of PD-L1 Attenuates the Positive Impacts of High-level Tumor-infiltrating Lymphocytes on Prognosis of Triple-negative Breast Cancer.

        Author: Zhu X1, Zhang Q2, Wang D1, Liu C1, Han B2, Yang JM3.

      • Visfatin is involved in the cisplatin resistance of osteosarcoma cells via upregulation of Snail and Zeb1.

        Author: Wang D1, Qian G1, Wang J1, Wang T1, Zhang L1, Yang P1, Lin F1.

      英文介紹

      Cancer Biology & Therapy雜志英文介紹

      Cancer, the second leading cause of death, is a heterogenous group of over 100 diseases. Cancer is characterized by disordered and deregulated cellular and stromal proliferation accompanied by reduced cell death with the ability to survive under stresses of nutrient and growth factor deprivation, hypoxia, and loss of cell-to-cell contacts. At the molecular level, cancer is a genetic disease that develops due to the accumulation of mutations over time in somatic cells. The phenotype includes genomic instability and chromosomal aneuploidy that allows for acceleration of genetic change. Malignant transformation and tumor progression of any cell requires immortalization, loss of checkpoint control, deregulation of growth, and survival. A tremendous amount has been learned about the numerous cellular and molecular genetic changes and the host-tumor interactions that accompany tumor development and progression. It is the goal of the field of Molecular Oncology to use this knowledge to understand cancer pathogenesis and drug action, as well as to develop more effective diagnostic and therapeutic strategies for cancer. This includes preventative strategies as well as approaches to treat metastases. With the availability of the human genome sequence and genomic and proteomic approaches, a wealth of tools and resources are generating even more information. The challenge will be to make biological sense out of the information, to develop appropriate models and hypotheses and to translate information for the clinicians and the benefit of their patients. Cancer Biology & Therapy aims to publish original research on the molecular basis of cancer, including articles with translational relevance to diagnosis or therapy. We will include timely reviews covering the broad scope of the journal. The journal will also publish op-ed pieces and meeting reports of interest. The goal is to foster communication and rapid exchange of information through timely publication of important results using traditional as well as electronic formats. The journal and the outstanding Editorial Board will strive to maintain the highest standards for excellence in all activities to generate a valuable resource.

      中科院SCI分區(qū)

      Cancer Biology & Therapy雜志中科院分區(qū)信息

      2023年12月升級版
      綜述:
      TOP期刊:
      大類:醫(yī)學(xué) 4區(qū)
      小類:

      ONCOLOGY
      腫瘤學(xué) 4區(qū)

      2022年12月升級版
      綜述:
      TOP期刊:
      大類:醫(yī)學(xué) 3區(qū)
      小類:

      ONCOLOGY
      腫瘤學(xué) 4區(qū)

      2021年12月舊的升級版
      綜述:
      TOP期刊:
      大類:醫(yī)學(xué) 3區(qū)
      小類:

      ONCOLOGY
      腫瘤學(xué) 4區(qū)

      2021年12月基礎(chǔ)版
      綜述:
      TOP期刊:
      大類:醫(yī)學(xué) 3區(qū)
      小類:

      ONCOLOGY
      腫瘤學(xué) 3區(qū)

      2021年12月升級版
      綜述:
      TOP期刊:
      大類:醫(yī)學(xué) 3區(qū)
      小類:

      ONCOLOGY
      腫瘤學(xué) 4區(qū)

      2020年12月舊的升級版
      綜述:
      TOP期刊:
      大類:醫(yī)學(xué) 3區(qū)
      小類:

      ONCOLOGY
      腫瘤學(xué) 4區(qū)

      中科院SCI分區(qū):是中國科學(xué)院文獻(xiàn)情報中心科學(xué)計量中心的科學(xué)研究成果。期刊分區(qū)表自2004年開始發(fā)布,延續(xù)至今;2019年推出升級版,實現(xiàn)基礎(chǔ)版、升級版并存過渡,2022年只發(fā)布升級版,期刊分區(qū)表數(shù)據(jù)每年底發(fā)布。 中科院分區(qū)為4個區(qū)。中科院分區(qū)采用刊物前3年影響因子平均值進(jìn)行分區(qū),即前5%為該類1區(qū),6%~20%為2區(qū)、21%~50%為3區(qū),其余的為4區(qū)。1區(qū)和2區(qū)雜志很少,雜志質(zhì)量相對也高,基本都是本領(lǐng)域的頂級期刊。

      JCR分區(qū)(2023-2024年最新版)

      Cancer Biology & Therapy雜志 JCR分區(qū)信息

      按JIF指標(biāo)學(xué)科分區(qū)
      學(xué)科:ONCOLOGY
      收錄子集:SCIE
      分區(qū):Q2
      排名:86 / 322
      百分位:

      73.4%

      按JCI指標(biāo)學(xué)科分區(qū)
      學(xué)科:ONCOLOGY
      收錄子集:SCIE
      分區(qū):Q2
      排名:98 / 322
      百分位:

      69.72%

      JCR分區(qū):JCR分區(qū)來自科睿唯安公司,JCR是一個獨特的多學(xué)科期刊評價工具,為唯一提供基于引文數(shù)據(jù)的統(tǒng)計信息的期刊評價資源。每年發(fā)布的JCR分區(qū),設(shè)置了254個具體學(xué)科。JCR分區(qū)根據(jù)每個學(xué)科分類按照期刊當(dāng)年的影響因子高低將期刊平均分為4個區(qū),分別為Q1、Q2、Q3和Q4,各占25%。JCR分區(qū)中期刊的數(shù)量是均勻分為四個部分的。

      CiteScore 評價數(shù)據(jù)(2024年最新版)

      Cancer Biology & Therapy雜志CiteScore 評價數(shù)據(jù)

      • CiteScore 值:7
      • SJR:0.914
      • SNIP:0.688
      學(xué)科類別 分區(qū) 排名 百分位
      大類:Medicine 小類:Oncology Q1 94 / 404

      76%

      大類:Medicine 小類:Pharmacology Q2 90 / 313

      71%

      大類:Medicine 小類:Cancer Research Q2 82 / 230

      64%

      大類:Medicine 小類:Molecular Medicine Q2 65 / 178

      63%

      歷年影響因子和期刊自引率

      投稿經(jīng)驗

      Cancer Biology & Therapy雜志投稿經(jīng)驗

      該雜志是一本國際優(yōu)秀雜志,在國際上有較高的學(xué)術(shù)影響力,行業(yè)關(guān)注度很高,已被國際權(quán)威數(shù)據(jù)庫SCIE收錄,該雜志在ONCOLOGY綜合專業(yè)領(lǐng)域?qū)I(yè)度認(rèn)可很高,對稿件內(nèi)容的創(chuàng)新性和學(xué)術(shù)性要求很高,作為一本國際優(yōu)秀雜志,一般投稿過審時間都較長,投稿過審時間平均 約2.3月 ,如果想投稿該刊要做好時間安排。版面費不祥。該雜志近兩年未被列入預(yù)警名單,建議您投稿。如您想了解更多投稿政策及投稿方案,請咨詢客服。

      免責(zé)聲明

      若用戶需要出版服務(wù),請聯(lián)系出版商:LANDES BIOSCIENCE, 1002 WEST AVENUE, 2ND FLOOR, AUSTIN, USA, TX, 78701。